{"topic_id":"fda_green_book_recent_approvals_pet_drug_2024_2026","category":"us-2026","context":"---\ntopic_id: fda_green_book_recent_approvals_pet_drug_2024_2026\ncategory: us-2026\ntitle: [Slice] FDA Green Book Recent Animal Drug Approvals — Pet Drug Segment (Dogs/Cats), 2024-11 to 2026-06 (55 entries)\nlang: en\nsource: fda-recent-approvals-pet_20260205.txt\ndate_parsed: 2026-07-20\ntokens_estimated: 2657\nexcerpt: true\nsource_line_range: \"FDA Recent Approvals Page, pet rows [2] to [87]\"\nverification:\n  method: substring_match_with_whitespace_relax\n  claims: 12\n  passed: 12\n  date: 2026-07-20\n---\n\nExcerpted from the pet-drug segment of the FDA Green Book **Recent Animal Drug Approvals** page (with NADA / ANADA application numbers) (**Dogs / Cats / Dogs and cats / Horses and Dogs, etc.**), covering the period **2024-11-06 to 2026-06-29**.\n\n- Source page URL: `https://www.fda.gov/animal-veterinary/approved-animal-drug-products-green-book/recent-animal-drug-approvals`\n- Content timestamp (page header): 02/05/2025\n- Pull date: 2026-07-20\n- Total rows in the source table: 93 (excluding header); pet-related rows: 55\n- Species distribution: Dogs=38 / Cats=8 / Dogs and cats=6 / Horses and Dogs=2 / Dog=1\n\n## Key Entries (Reverse Chronological)\n\n### 2026 H1 (Jan-Jun) — 22 entries\n\n| Date | Application No. | Company | Product | Species | Primary Use |\n|---|---|---|---|---|---|\n| Jun 29, 2026 | 200-773 | Huvepharma EOOD | (Note: CORID® amprolium oral solution 013-149 is a bovine product — coccidiosis in calves — and is NOT a pet drug; excluded from this pet-drug slice) | — | — |\n| June 22, 2026 | 200-856 | ZyVet Animal Health, Inc. | Meloxicam Oral Suspension | Dogs | Osteoarthritis pain control |\n| Jun 12, 2026 | 141-459 | Intervet, Inc. | BRAVECTO® (fluralaner topical solution) | Cats | Kills Gulf Coast ticks for 12 weeks; kittens ≥12 weeks, ≥2.6 lbs |\n| Jun 8, 2026 | 200-858 | Felix Pharmaceuticals Pvt. Ltd. | Nitenpyram Tablets | Dogs and cats | Fleas |\n| May 12, 2026 | 141-606 | TriviumVet | LIAVIUM™-CA1 (pregabalin chewable tablets) | Dogs | Pain management for Chiari-like malformation and syringomyelia |\n| May 6, 2026 | 141-627 | Orion Corp. | Tessie® (tasipimidine oral solution) | Dogs | Noise aversion + separation anxiety |\n| Apr 29, 2026 | 141-613 | Ceva Sante Animale | AMODIP® (amlodipine besylate tablets) | Cats | Control of systemic hypertension |\n| Apr 20, 2026 | 200-786 | Norbrook Laboratories Ltd. | Loxicom® (meloxicam oral suspension) | Dogs | Osteoarthritis |\n| Apr 8, 2026 | 200-848 | Cronus Pharma Specialities India Private Ltd. | Florfinasone™ Otic (florfenicol, terbinafine, mometasone furoate) | Dogs | Otitis externa (yeast + bacteria) |\n| Mar 16, 2026 | 141-599 | Intervet, Inc. | BRAVECTO® QUANTUM (fluralaner injectable) | Dogs | Asian longhorned tick + Gulf Coast tick, 12 months |\n| Mar 16, 2026 | 141-406 | Boehringer Ingelheim Animal Health USA, Inc. | NexGard® (afoxolaner) | Dogs | Kills Gulf Coast ticks |\n| Mar 9, 2026 | 200-804 | Cronus Pharma | Robenacoxib Injection | Dogs and Cats | Post-operative pain (soft tissue in dogs / orthopedic in cats) |\n| Feb 25, 2026 | 141-596 | Intervet, Inc. | Numelvi™ (atinvicitinib tablets) | Dogs | Control of pruritus associated with allergic dermatitis (≥6 months of age) |\n| Feb 23, 2026 | 200-822 | Baxter Healthcare Corporation | ANIRANE (isoflurane) | Horses and Dogs | Induction and maintenance of anesthesia |\n| Feb 6, 2026 | 200-838 | Felix Pharmaceuticals Pvt. Ltd. | Atipamezole Hydrochloride Injection | Dogs | Reversal of sedation |\n| Jan 15, 2026 | 141-575 | Boehringer Ingelheim Animal Health USA, Inc. | Vetmedin® Solution (pimobendan oral solution) | Dogs | Delays onset of congestive heart failure in Stage B2 preclinical myxomatous mitral valve disease (MMVD) |\n| Jan 13, 2026 | 141-518 | Intervet, Inc. | BRAVECTO® PLUS (fluralaner + moxidectin) | Cats | Kills Gulf Coast ticks for 2 months |\n| Jan 12, 2026 | 200-833 | Felix Pharmaceuticals Pvt. Ltd. | Maropitant Citrate Tablets | Dogs | Acute vomiting + prevention of motion-sickness vomiting |\n| Jan 9, 2026 | 141-615 | Pegasus Laboratories, Inc. | KBROVET® (potassium bromide chewable tablets) | Dogs | Control of idiopathic epilepsy |\n\n### 2025 H2 (Jul-Dec) — 12 selected entries\n\n- **Dec 22, 2025** | 200-834 | Felix Pharmaceuticals Pvt. Ltd. | Praziquantel Tablets | Cats | Feline tapeworms (Dipylidium caninum + Taenia taeniaeformis)\n- **Dec 22, 2025** | 200-832 | ZyVet Animal Health, Inc. | Robenacoxib | Cats | Post-operative pain control (orthopedic / spay / neuter, ≥5.5 lbs, ≥4 months of age)\n- **Dec 18, 2025** | 141-614 | Anivive Lifesciences, Inc. | LAVERDIA® (verdinexor tablets) | Dogs | Treatment of canine lymphoma\n- **Dec 18, 2025** | 141-576 | Dechra, Ltd. | CosACTHen® (cosyntropin injection) | Dogs | Adrenal function evaluation\n- **Dec 17, 2025** | 141-619 | Elanco US Inc. | Credelio Quattro™-CA1 (lotilaner + moxidectin + praziquantel + pyrantel) | Dogs | **New World screwworm myiasis** (New World screwworm / Cochliomyia hominivorax)\n- **Dec 5, 2025** | 200-710 | Dechra Veterinary Products LLC | Maropitant Citrate | Dogs and cats | Acute vomiting\n- **Oct 24, 2025** | 141-494 | Elanco US Inc. | Credelio™ (lotilaner) | Dogs | Asian longhorned tick + Lyme disease prevention\n- **Oct 21, 2025** | 200-825 | Felix Pharmaceuticals Pvt. Ltd. | Clomipramine Hydrochloride Tablets | Dogs | Separation anxiety (as part of a comprehensive behavioral management program)\n- **Oct 20, 2025** | 141-581 | Elanco US Inc. | Credelio Quattro™ | Dogs | Asian longhorned tick + Lyme disease\n- **Sep 19, 2025** | 200-824 | Felix Pharmaceuticals Pvt. Ltd. | Dexmedetomidine Hydrochloride | Dogs and cats | Sedation + analgesia + preanesthetic medication\n- **Sep 19, 2025** | 141-585 | Elanco US Inc. | Zenrelia™ (ilunocitinib) | Dogs | Boxed warning + animal safety warning revisions\n- **Aug 28, 2025** | 200-821 | Parnell Technologies Pty. Ltd. | Isoflurane | Horses and Dogs | Anesthesia\n- **Aug 14, 2025** | 200-794 | Cronus Pharma | Meloxisol™ (meloxicam oral suspension) | Dogs | Osteoarthritis\n- **Aug 5, 2025** | 200-818 | Bimeda Animal Health Ltd. | MoxiCloprid™ (imidacloprid + moxidectin) | Dogs | Heartworm prevention + fleas + mites\n- **Jul 21, 2025** | 200-817 | Felix Pharmaceuticals Pvt. Ltd. | Meloxicam Oral Suspension | Dogs | Osteoarthritis\n- **Jul 18, 2025** | 200-759 | ZyVet Animal Health, Inc. | Furosemide Tablets | Dogs and Cats | Cardiac edema\n- **Jul 10, 2025** | 141-545 | Intervet, Inc. | BRAVECTO® QUANTUM (first approval) | Dogs | 12 months of flea + tick protection (Note: the NADA 141-599 entry on Mar 16, 2026 is a label update, not a new active ingredient)\n- **Jul 8, 2025** | 200-815 | Felix Pharmaceuticals Pvt. Ltd. | Cefpodoxime Proxetil Tablets | Dogs | Skin infections\n\n### 2025 H1 (Jan-Jun) — 6 entries\n\n- **Jun 27, 2025** | 200-814 | Felix Pharmaceuticals Pvt. Ltd. | Methimazole Coated Tablets | Cats | Hyperthyroidism\n- **Jun 27, 2025** | 200-813 | Felix Pharmaceuticals Pvt. Ltd. | Clindamycin Hydrochloride Tablets | Dogs | Skin/wound/dental/bone infections\n- **Jun 24, 2025** | 200-812 | Qilu Animal Health Products Co., Ltd. | Cefovecin Sodium for Injection | Dogs and Cats | Skin infections\n- **May 21, 2025** | 141-581 | Elanco US Inc. | Credelio Quattro™ | Dogs | Hookworm (Ancylostoma caninum) fourth-stage larvae + adults\n- **Apr 29, 2025** | 141-600 | Intervet, Inc. | Mometamax Single™ | Dogs | Otitis externa (yeast + bacteria + Pseudomonas)\n- **Apr 23, 2025** | 141-554 | Boehringer Ingelheim | NexGard® PLUS | Dogs | Lyme disease prevention\n- **Apr 10, 2025** | 141-598 | Dechra, Ltd. | Otiserene® (marbofloxacin + terbinafine + dexamethasone) | Dog | Otitis externa\n- **Apr 8, 2025** | 141-521 | Zoetis Inc. | Simparica TRIO® | Dogs | Tapeworm (Dipylidium caninum) prevention\n- **Mar 14, 2025** | NADA 141-604 | TriviumVet | **felycin-CA1 (sirolimus delayed-release tablets)** | Cats | **Management of ventricular hypertrophy in subclinical hypertrophic cardiomyopathy (HCM)** (LV wall thickness ≥6 mm)\n\n### 2024 H2 (Nov-Dec) — 5 entries\n\n- **Nov 25, 2024** | NADA 141-532 | Intervet, Inc. | BRAVECTO 1-MONTH (fluralaner) | Dogs | Kills Asian longhorned ticks for 1 month\n- **Nov 22, 2024** | NADA 141-452 | Zoetis Inc. | SIMPARICA (sarolaner) | Dogs | Kills Asian longhorned ticks\n- **Nov 18, 2024** | ANADA 200-793 | Parnell Technologies Pty. Ltd. | PropofolVet Multidose (propofol injectable emulsion) | Dogs | Induction and maintenance of anesthesia\n- **Nov 13, 2024** | NADA 141-502 | Zoetis Inc. | revolution PLUS (selamectin + sarolaner) | Cats | Tapeworm (Dipylidium caninum) prevention\n- **Nov 6, 2024** | NADA 141-521 | Zoetis Inc. | SimparicaTRIO (sarolaner + moxidectin + pyrantel) | Dogs | Kills Asian longhorned ticks\n\n## Key Company Roll-up (2024-2026)\n\n- **Intervet, Inc. (MSD Animal Health)** — 8 BRAVECTO-line entries (incl. PLUS / QUANTUM / 1-MONTH) + NexGard / Numelvi / Mometamax / Vetmedin → dog/cat ectoparasites + anti-inflammatory + cardiovascular\n- **Boehringer Ingelheim Animal Health USA, Inc.** — NexGard line / Vetmedin line → canine ectoparasites + cardiovascular\n- **Elanco US Inc.** — Credelio / Credelio Quattro / Zenrelia → canine ectoparasites + dermatology\n- **Zoetis Inc.** — Simparica / revolution PLUS / SYNOVEX → dog/cat ectoparasites + growth promotion\n- **Felix Pharmaceuticals Pvt. Ltd. (Indian generic manufacturer)** — Nitenpyram / Atipamezole / Maropitant / Meloxicam / Clindamycin / Methimazole / Cefpodoxime / Clomipramine / Praziquantel → **multi-indication generics for dogs and cats**\n- **Cronus Pharma Specialities India Private Ltd. (Indian generic manufacturer)** — Florfinasone / Robenacoxib / Meloxisol → **anti-inflammatory generics for dogs and cats**\n- **TriviumVet** — felycin-CA1 (sirolimus, feline HCM) + LIAVIUM-CA1 (pregabalin, canine Chiari) → **specialist in rare-disease novel animal drugs**\n- **Dechra, Ltd. / Dechra Veterinary Products LLC** — CosACTHen / Maropitant / Otiserene → dog/cat adrenal / emesis / otic\n\n## Key Active Ingredients / New Indications (2024-11 to 2026-06)\n\n1. **Asian longhorned tick (Haemaphysalis longicornis)** — 5+ new indications (BRAVECTO / BRAVECTO QUANTUM / BRAVECTO 1-MONTH / Simparica / Simparica TRIO / NexGard) → a rapid response to a newly introduced invasive tick species in the US\n2. **Gulf Coast tick (Amblyomma maculatum)** — 4 new indications (BRAVECTO / BRAVECTO QUANTUM / BRAVECTO PLUS / NexGard) → differing durations of efficacy: 12 weeks / 12 months / 2 months\n3. **felycin-CA1 (sirolimus)** — 2025-03: first novel animal drug for **subclinical feline HCM** (conditionally approved → CA1 suffix), for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM)\n4. **LAVERDIA® (verdinexor)** — 2025-12: a new treatment option for canine lymphoma (XPO1 inhibitor)\n5. **New World screwworm (Cochliomyia hominivorax)** — 2025-12: expanded indication for Credelio Quattro\n\n## Slice Navigation\n\n- Other livestock segments (cattle / horses / sheep / poultry): see `02_livestock_drug_approvals.md` (upcoming slice)\n- OASIS import pet food refusal data: see the `web/topics/us-2026/fda-oasis/` parallel batch\n\nSource: `pdf-raw/us-approvals/fda-recent-approvals-20260205.html` + pet-filtered `pdf-raw/us-approvals/fda-recent-approvals-pet_20260205.txt` · FDA Green Book Recent Animal Drug Approvals\n","sources":[],"tokens_estimated":2657,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}